Systemic lupus erythematosus (SLE) is a chronic inflammatory disorder of autoimmune etiology with multisystemic affection. SLE represents a high burden on general health world widely as it causes high morbidity and mortality rates. Lupus nephritis (LN) is a severe organ lesion form which affect high percentage of SLE patients and may end by developing of end-stage renal disease (ESRD) or even death. Urokinase plasminogen activator receptor (uPAR) is a membrane-bound receptor which is mainly expresses on the membrane of immunologically active cells and is involved in many physiological and pathological processes, such as inflammation and immune responses. Soluble urokinase plasminogen activator receptor (suPAR) is derived from shedding of the uPAR and is expressed on a variety of cells, including neutrophils, lymphocytes, macrophages, and endotheliocytes. Recent evidences indicate that suPAR is involved in various biological functions, including cell adhesion, migration, and chemotaxis, and its elevated level is associated with poor clinical outcomes in various inflammatory diseases, such as sepsis, bacteremia, and systemic inflammatory response syndrome. Assessment of disease activity and organ damage in SLE remains challenging due to lack of reliable biomarkers and to heterogeneity of the disease. Additionally, it can be difficult to distinguish ongoing inflammation from permanent organ damage caused by previous flares or medication side effects. The suPAR has emerged as a potential marker of inflammation and disease severity, as well as a predictor of outcome of several disparate conditions

Soluble Urokinase Plasminogen Activator Receptor - Predictor – Renal Damage – Systemic Lupus Patients